Forest Hills Business Association

Forest Hills Lab (FHL) is a clinical-stage biopharmaceutical company focused on developing regenerative therapies for neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and traumatic brain injury (TBI). The company's lead candidate, FHL-101 (glyceryl tribenzoate), is an oral small molecule that induces the expression of Glial cell-line Derived Neurotrophic Factor (GDNF) to support neuronal function and suppress inflammation. FHL operates through three synergistic divisions: Therapeutics, Aesthetics (focused on injectable treatments), and Awakening Health Lab (specializing in AI-driven healthcare robotics). Headquartered in Hong Kong with operations in the United States and South Korea, the company utilizes a hub-and-spoke model to advance its multi-modal pipeline of disease-modifying neurological assets.